ANI Pharmaceuticals shows raised 2025 guidance at June 4 Jefferies conference
ANI Pharmaceuticals filed its investor presentation for the Jefferies Global Healthcare Conference, where CEO Nikhil Lalwani will speak on June 4, 2025. The slides restate 2025 guidance issued on May 9, 2025, which the company describes as its second guidance raise of the year, and they report first-quarter 2025 revenue and profit growth. The filing presents previously disclosed figures rather than new results, but the guidance increase is relevant to shareholders.
- 2025 net revenue guidance is $768 million to $793 million, up from $756 million to $776 million previously.
- 2025 adjusted non-GAAP EBITDA guidance is $195 million to $205 million, up from $190 million to $200 million; adjusted diluted EPS guidance is $6.27 to $6.62, up from $6.12 to $6.49.
- First-quarter 2025 total revenue was $197 million, up 43% year over year, and adjusted non-GAAP EBITDA was $51 million, up 35%.
- Q1 ILUVIEN and YUTIQ revenue of $16 million was temporarily affected by factors the company listed, including sales force turnover; the company said demand accelerated in Q2 2025.